Taiwanese Version of the EQ-5D: Validation in a Representative Sample of the Taiwanese Population  by Chang, Ting-Jung et al.
J Formos Med Assoc | 2007 • Vol 106 • No 12 1023
A number of instruments have been developed to
measure health-related quality of life (HRQOL).1
One such instrument is the EuroQol, or EQ-5D.2,3
The EQ-5D is a preference-based instrument
based on multi-attribute health-status classifiers.
Population-specific health-state preferences have
been derived for this tool. This instrument is
being used with increasing frequency in both clin-
ical and health services research, and it has been
validated in numerous international studies.4–6
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Background/Purpose: We know of no validated Taiwanese-language instrument to measure a utility of
the patient’s health. Our aim was to evaluate the reliability and validity of a Taiwanese version of the
EuroQol instrument (EQ-5D) in a Taiwanese population.
Methods: Questionnaires containing the Taiwanese versions of the EQ-5D and the Short-Form 12 Health
Survey (SF-12) were sent to 12,923 people in Taiwan in December 2002. Concurrent validity of the EQ-5D
was analyzed by assuming that subjects with problems in any EQ-5D dimensions had decreased SF-12
scores. Discriminant validity of the EQ-5D was analyzed by assuming that subjects with the following
characteristics had lowered EQ-5D indexes and scores on the EQ-5D visual analog scale (VAS): more
chronic diseases than others, serious illness, more hospitalizations in the past year than others, poor 
general health, and more outpatient visits than others. Test–retest reliability was analyzed in a subgroup of
respondents who were evaluated twice within a month by using the intraclass correlation coefficient and
the κ method.
Results: The general survey response rate was 12.7% (1644 of 12,923). SF-12 scores were lower in subjects
reporting problems on EQ-5D dimensions than in others without such problems (p < 0.01). Subjects with
more health problems than others had lower EQ-5D indexes and VAS scores (p < 0.01). The physical 
dimension of the EQ-5D was more strongly correlated with the SF-12 Physical Component Summary 
than with the Mental Component Summary; this finding satisfied the a priori hypothesis. For test–retest
reliability of items on the EQ-5D, κ values ranged from 0.49 to 1 (p < 0.001).
Conclusion: The Taiwanese EQ-5D instrument appears to be a moderately valid and reliable tool for meas-
uring the health status of the general population in Taiwan. [J Formos Med Assoc 2007;106(12):1023–1031]
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ORIGINAL ARTICLE
The EQ-5D has been translated into many lan-
guages, including 60 official versions.7,8 The use-
fulness and the construct validity of the various
language versions of the EQ-5D have been tested
in different community respondents and patient
groups, including patients examined in general
practice, those with rheumatoid arthritis, and those
receiving cardiac rehabilitation.9–12 Its generic char-
acter, proven efficacy, and brevity make the EQ-5D
particularly attractive for use in the assessment of
patients and in the economic evaluation of med-
ications and treatments.
The aforementioned preferences for the EQ-5D
have been most extensively linked to the prefer-
ences of the general population of the United
Kingdom and the United States.1,13,14 However,
how these preferences apply to the Taiwanese
population remains unclear. Moreover, to our
knowledge, the psychometric properties of the
Taiwanese version of the EQ-5D have not been
assessed in Taiwan.
The purposes of this study were to evaluate the
construct and concurrent validity as well as the
test–retest reliability of the Taiwanese version of
the EQ-5D in a large random sample of the gen-
eral population in Taiwan.
Methods
Subjects and study design
The island of Taiwan comprises 22 cities and coun-
ties. The population in these geographical areas
aged 20–64 years in 2000 (roughly 14 million citi-
zens) was the sampling frame. According to data
from the Measurement and Valuation of Health
study by the EuroQol Group, an estimated sample
of at least 1618 is needed to achieve a significant
difference of 0.05 among individual health sta-
tuses, with an α value of 0.05 and a β value of 0.2.15
Because of the difficulty in answering the question-
naire, we assumed a low response rate of around
15%. Therefore, we conducted oversampling of
12,923 individuals. They were randomly selected
by applying a probability proportional to the sizes
of the population of each city and county.
To conduct this postal survey, we mailed a ques-
tionnaire containing the EQ-5D and the Short-
Form 12 Health Survey (SF-12) version 1 to these
subjects in December 2002.2 The EQ-5D ques-
tionnaire contained an EQ-5D self-classifier, 
a visual analog scale (VAS), sociodemographic
questions (SDQ), and a 16-item health-status
valuation questionnaire. Because of the difficulty
of answering the valuation questionnaire, we ex-
cluded individuals who were older than 64 years
or younger than 20 years.
Two weeks after we mailed the first question-
naire, we sent a reminder to individuals who had
not responded. The original questionnaire and
an explanation letter were sent to individuals
whose answers were incomplete. A gift of NT$50
was sent to each respondent.
In the first questionnaire, the SDQ, an item
asked if the subject would be willing to receive
another similar questionnaire in the future. Re-
spondents who responded yes were the candidates
for retesting. We randomly selected 302 retest sam-
ples from 1145 respondents who consented to re-
ceive a second questionnaire. Retest measurement
was conducted within 1 month.
Instruments
With the EQ-5D, a single index score of –0.59 
to 1.00 can be generated for each respondent. The
EQ-5D value set was first developed by using 
a time trade-off technique for a sample of these
health states from a representative sample of 
the general population in the United Kingdom.3
EQ-5D scores are calculated by subtracting the rel-
evant tariffs from 1. For example, for health state
11223, the preference value is 1 – 0.036 – 0.123 –
0.236 – 0.269 – 0.081 = 0.225, where a negative
value means that a health state is worse than death.
The EQ-5D self-classifier assesses the five di-
mensions of mobility, self-dare, usual activity, pain/
discomfort, and anxiety/depression on three levels
(none, moderate, extreme). The VAS consisted of
a 20-cm, vertical scale. Respondents were asked to
classify and rate their health status on the day of the
survey. The SDQ consisted of sociodemographic
data and supplementary clinical information.
T.J. Chang, et al
1024 J Formos Med Assoc | 2007 • Vol 106 • No 12
The last part was the 16-health status valuation
questionnaire, which was designed to create the
tariffs to calculate the preference value of every
health state for another study; these data were not
used for this validation study.
In developing the Taiwanese EQ-5D instru-
ment, an official Taiwanese version was obtained
from the EuroQol Group; however, it is not a val-
idated instrument in Taiwan.8 We independently
created another translation of the English version.
The final Taiwanese document was translated back
into English and sent to the EuroQol Group for re-
view. The wording of one item was not appropri-
ate, and the Taiwanese characters were corrected.
Two other words were changed to standardized
translation terms. The Taiwanese EQ-5D was ad-
ministered to 10 native Chinese-speaking Taiwan
ese from diverse sociodemographic backgrounds.
In this pilot study, subjects commented on the
demographic part of the instrument, and changes
were made when necessary. This final Taiwanese
version was used in the validation study.
The SF-12 consists of 12 items measuring phys-
ical and mental health, and it yields two summary
scores: the Mental Component Summary (MCS)
and Physical Component Summary (PCS). High
scores reflect improved health status. The Chinese
Short Form-36 (SF-36) has been shown to be reli-
able and valid in general or medical popula-
tions.16,17 The Chinese version of the SF-12 was
derived from the validated version of the Chinese
SF-36, and its exact wording was used in this study.
Data analysis
Concurrent validity of the EQ-5D was analyzed
by making two assumptions. The first assump-
tion was that subjects with some/moderate or ex-
treme problems on any EQ-5D dimension have
SF-12 PCS and MCS scores that are lower than
those of other subjects. The second assumption
was that today’s (the testing day’s) EQ-5D index
or EQ VAS score is highly correlated with the 
SF-12 PCS and SF-12 MCS scores in the recent
month.18,19 Pearson’s correlation coefficients were
used to describe correlations among the EQ index,
the VAS score, and the SF-12 subscale scores. For
the EQ-5D index, we used EQ-5D weights derived
from the general population of Japan; for the
SF-12 PCS and SF-12 MCS scores, we used SF-12
weights derived from the general population of
the United States.3,20,21
Discriminant validity of the EQ-5D was ana-
lyzed by assuming that subjects with the follow-
ing characteristics had lowered EQ-5D indexes
and VAS scores: more chronic diseases than other
subjects, serious illness, more hospitalizations 
in the past year than other subjects, poor general
health, and more outpatient visits in the past 
2 weeks than other subjects.3,10,14 For the EQ-5D
index, we used EQ-5D weights derived from the
general population of the United Kingdom and
Japan.
Convergent validity was analyzed by assuming
a high correlation between EQ-5D physical dimen-
sion scores (i.e. mobility, self-care, usual activities,
or pain/discomfort) and SF-12 PCS scores and
between EQ-5D mental dimension scores (i.e.
anxiety/depression) and SF-12 MCS scores.12,22
Divergent validity was analyzed by assuming
a low correlation between EQ-5D physical dimen-
sion scores and SF-12 MCS scores and between
EQ-5D physical dimension scores and EQ-5D
mental dimension scores. For the EQ-5D dimen-
sion, we used EQ-5D weights derived from the gen-
eral population of Japan.
Pearson’s correlation coefficients were used to
describe correlations among the EQ-5D dimension
and the SF-12 subscale scores. Spearman’s correla-
tion coefficients were used to describe correlations
among the EQ-5D dimensions. Coefficients ≥ 0.5
indicated a strong correlation; 0.35–0.50 a mod-
erate correlation; and < 0.35 a weak correlation.23
Test–retest reliability of EQ-5D indexes and
VAS scores was determined by using intraclass
correlation coefficients (ICCs), and response
consistency on the five dimensions of the EQ-5D
was determined by using the agreement method
and Cohen’s κ.24 An ICC ≥ 0.7 is considered ac-
ceptable for test–retest reliability.25 Values < 0.4
indicated poor agreement; 0.41–0.6 indicated
moderate agreement; 0.61–0.8 substantial agree-
ment; and > 0.8 almost perfect agreement.26
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Reliability of the EQ-5D was assessed by cor-
relating the first and retest sets of scores for subjects
who indicated no change on the today’s health sta-
tus transition question. The question was: “com-
pared with my general level of health over the past
12 months, my health state today is: better, much
the same, worse.”
Data were analyzed using STATA version 7.0
(StataCorp LP, College Station, TX, USA) and SPSS
version 13 (SPSS Inc., Chicago, IL, USA). Analysis
of variance and independent t test were used to
test for differences in mean scores among groups
with different attribute variables. Scheffé’s test
was used for post hoc comparisons. A χ2 test was 
performed to evaluate sample characteristics. 
A p value of less than 0.05 indicated significant 
difference.
Results
We sent questionnaires to 12,923 individuals from
the general population, 1768 of whom returned
them. Questionnaires from 1644 were valid for
analysis. Therefore, the survey response rate was
12.7%. The exclusion criterion was a missing 
response to any item on the SF-12 or EQ-5D 
self-classifier.
The Figure shows the geographic distributions
of people aged 20–64 years in the general popu-
lation of Taiwan,27 of the sample given the postal
survey, and of respondents. For these groups, the
distribution trends were almost the same.
Table 1 summarizes the comparative informa-
tion regarding the Taiwanese population and the
response sample. The mean age (± standard devi-
ation) of the respondents was 41.9 ± 12.1 years
(range, 20–64 years). Many respondents were
highly educated and unemployed. About 45%
had at least a college education. The mean age of
the respondents was almost the same as that 
of the 12,923 individuals who were sampled
(mean age, 41.7 years) and similar to that of the
population 20–64 years (mean age, 39.4 years).
Tables 2 and 3 provide the evidence of con-
current validity. Subjects with no or some/
moderate problems on any EQ-5D dimension
had increased or decreased scores on the SF-12
PCS and MCS, respectively (p < 0.01, t test; Table
2). Because fewer than 30 respondents with us-
able data reported extreme problems, the extreme
category was combined with the some/moderate
T.J. Chang, et al
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Figure. Geographical distributions of the 
general Taiwanese population, postal survey
samples and respondents aged 20–64 years.
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Table 1. Characteristics of 1644 respondents aged 20–64 years
Response sample Population
n Mean (SD) % % Mean
Age 1618 41.9 (12.1) 39.4†
Salary in past 1 yr (US$) 1400 11,991 (10,839)
Inpatient visits in past 1 yr 1632 0.1 (0.6)
Outpatient visits in past half mo 1631 0.9 (2.4)
Out of pocket expenses for disease in 1489 335 (683)
past 1 yr (US$)
Female 828 50.4 49.6
Marital status
Unmarried/separated/divorced 488 29.7 32.1
Married 1089 66.2 65.4
Widowed 49 3.0 2.4
Education level*
≤ Senior high school 843 51.3 72.1
College or university 649 39.5 25.8
≥ Master’s degree 88 5.4 2.2
Employment status*
Employed 1068 65.0 70.6
Unemployed/homemaker/retired 545 33.2 29.4
*p < 0.01, χ2 test; †estimated mean age = (subgroup median age × number of people in subgroup) ÷ (number of people aged 20–64
years). SD = standard deviation.
Table 2. Test of concurrent validity (n = 1644)*
EQ-5D dimension n SF-12 PCS† SF-12 MCS†
Mobility
No problem 1581 50.4 45.6
With problem 63 34.4 39.2
Self-care
No problem 1619 50.0 45.4
With problem 25 32.0 37.6
Usual activity
No problem 1531 50.7 46.0
With problem 113 36.6 36.8
Pain/discomfort
No problem 1111 52.5 47.1
With problem 533 44.0 41.6
Anxiety/depression
No problem 1175 50.8 48.6
With problem 469 47.1 37.2
*All p < 0.01, independent t test; †using US Norm-Based Standardization of Scale Scores Weight. PCS = Physical Component Summary;
MCS = Mental Component Summary.
category. EQ-5D indexes and VAS scores on the
study day were moderately to strongly correlated
with SF-12 PCS and SF-12 MCS scores in the 
recent month (Table 3).
For each EQ-5D dimension, subjects reported
(moderate or extreme) problems (Table 2). Dimen-
sions in which subjects reported the most prob-
lems were pain/discomfort (moderate, n = 519
[31.6%]; extreme, n = 14 [0.9%]), followed by
anxiety/depression problems (moderate, n = 450
[27.4%]; extreme, n = 19 [1.2%]).
Subjects who reported serious illnesses, poor
general health on the testing day, more outpa-
tient visits, inpatient visits, and chronic diseases
than other subjects had low EQ-5D indexes and
EQ VAS scores (p < 0.01, t test; Table 4).
Table 5 shows the data for convergent and di-
vergent validity. The EQ-5D had two dimensions:
mental health (anxiety/depression) and physical
health (mobility, self-care, usual activities, pain/
discomfort). Convergent validity was demonstrated
by the response on EQ-5D physical health dimen-
sion, which was correlated more with the SF-12
PCS (r = 0.26–0.51) than with the SF-12 MCS
(r=0.09–0.26). Additional evidence came from the
response to the anxiety dimension of the EQ-5D,
which was more strongly correlated with the SF-12
MCS (r=0.53) than with the PCS (r=0.22). Diver-
gent validity was demonstrated by the response to
the EQ-5D physical health dimension, which was
T.J. Chang, et al
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Table 3. Correlation of SF-12 subscale, EQ-5D
index, EQ VAS score for concurrent
validity (n = 1644)
SF-12 PCS* SF-12 MCS*
SF-12 MCS* 0.10 –
EQ-5D index† 0.53‡ 0.42‡
EQ VAS score 0.45‡ 0.49‡
*Using US Norm-Based Standardization of Scale Scores Weight;
†using Japanese TTO value set; ‡hypotheses which are supported.
PCS = Physical Component Summary; MCS = Mental Component
Summary.
Table 4. Test of discriminant validity
Health condition EQ-5D index* (n) EQ-5D index† (n) EQ VAS score (n) Assumption
Experienced serious illness
No 0.81 (1468) 0.86 (1468) 79.3 (1423)
Yes 0.72 (173) 0.70 (173) 64.3 (168) No > Yes‡
General health today
Excellent 0.84 (62) 0.89 (62) 91.8 (61)
Very good 0.83 (597) 0.89 (597) 86.4 (585)‡ Excellent > Very good
Good 0.81 (452) 0.85 (452) 77.3 (436) Very good > Good‡
Fair 0.76 (462) 0.79 (462) 68.3 (444) Good > Fair‡
Poor 0.64 (57) 0.54 (57) 50.6 (55) Fair > Poor‡
Outpatient visits in past 
half mo
0 0.82 (1090) 0.87 (1090) 80.7 (1060)
1–2 0.77 (395) 0.81 (395) 73.4 (380) 0 > 1–2‡
≥ 3 0.73 (145) 0.74 (145) 67.0 (140) 1–2 > ≥ 3‡
Inpatient visits in past yr
0 0.80 (1526) 0.85 (1526) 78.4 (1483)
≥ 1 0.73 (106) 0.73 (106) 68.4 (99) 0 > ≥ 1‡
Number of chronic diseases
0 0.82 (687) 0.88 (687) 82.4 (669)
1–2 0.79 (847) 0.83 (847) 76.0 (820) 0 > 1–2‡
≥ 3 0.72 (110) 0.71 (110) 61.9 (105) 1–2 > ≥ 3‡
*Using Japanese TTO value set; †using UK TTO value set; ‡p < 0.01, ANOVA or independent t test.
weakly correlated with the SF-12 MCS (r = 0.09–
0.26). Also supporting divergent validity was the
response to the EQ-5D anxiety dimension, which
was also weakly correlated with the SF-12 PCS
(r=0.22). Divergent validity was also demonstrated
by the weak correlation (ρ = 0.11–0.26) between
results from the EQ-5D physical and mental di-
mensions, with the exception of pain/discomfort
(ρ = 0.40).
In the retest samples, 184 of 302 subjects re-
turned the retest questionnaire, and results of 112
were usable for analysis. The test–retest survey re-
sponse rate was 37.1%. The exclusion criteria were
any missing item on the SF-12 or EQ-5D self-
classifier (n=4), a difference in sex between the test
and retest surveys (n = 6), a 1-year difference in age
between the test and retest surveys (n = 14), and a
change in the subject’s health status on the testing
day between the test and retest surveys (n = 48).
The ICCs of reliability were 0.51 (95% confi-
dence interval [CI], 0.36–0.63; p < 0.000) for the
EQ-5D index and 0.70 (95% CI, 0.58–0.78;
p < 0.000) for the VAS score. Agreements for EQ-5D
items regarding mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression were
98.2%, 100%, 98.2%, 84.8%, and 83%, respec-
tively; Cohen’s κ values for these items were 0.49
(95% CI, 0.31–0.68; p < 0.0001), 1.0, 0.74 (95%
CI, 0.56–0.92; p < 0.0001), 0.58 (95% CI, 0.40–
0.76; p < 0.0001), and 0.50 (95% CI, 0.32–0.67;
p < 0.0001), respectively (n = 112; interval, 3–5
weeks). The study demonstrated moderate 
evidence to support test–retest reliability of the
Taiwanese version of the EQ-5D classifier.
Discussion
This study represents the first application of the
Taiwanese version of the EQ-5D, a generic instru-
ment, in a large and representative population 
in Taiwan. The respondents appeared to be well
represented in terms of geography, age, sex and
marital status. However, their education level and
unemployment rate were higher than those in
the general population of people aged 20–64
years. The EQ-5D questionnaire contained a self-
classifier, a VAS, and SDQ, as well as a 16-health
status valuation questionnaire that was difficult
to answer. Individuals with high levels of educa-
tion might have been able to answer the 16-
health status valuation questionnaire more easily
than others, and unemployed people might have
had more time to answer the questions than 
others.
Two possible reasons for the low response rate
were difficulty in answering the valuation ques-
tionnaire and the fact that the questionnaires were
mailed. Offering NT$50 as an incentive, we re-sent
questionnaires to non-respondents and to respon-
dents whose answers were incomplete; however,
the response rate did not increase much.
The EQ-5D and SF-12 have similar constructs;
correlations among the EQ-5D, SF-12 PCS and
SF-12 MCS were moderate. Petrou and Hockley
reported that the correlation coefficients for the
EQ-5D with the SF-12 PCS and the MCS were
0.65 and 0.54 respectively, whereas coefficients
for the EQ-VAS with the SF-12 PCS and MCS were
0.65 and 0.44, respectively (n = 321).28 We found
Taiwanese version of the EQ-5D 
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Table 5. Correlation of the SF-12 subscales and five dimensions of the EQ-5D for convergent and divergent
validity (n = 1644)*†
EQ-5D SF-12 PCS‡ SF-12 MCS‡ Anxiety/depression§
Mobility –0.32 –0.11 0.14
Self-care –0.26 –0.09 0.11
Usual activity –0.41 –0.24 0.26
Pain/discomfort –0.51 –0.26 0.40
Anxiety/depression –0.22 –0.53 –
*Hypotheses are shown for convergent validity (bold) and divergent validity (bold italics), and hypotheses which are supported are 
underlined; †coefficients ≥ 0.5 indicate strong correlation, 0.35–0.50 moderate correlation, and < 0.35 weak correlation; ‡Pearson’s
correlation; §Spearman’s correlation. PCS = Physical Component Summary; MCS = Mental Component Summary.
that the correlations between these instruments
were moderate to strong (Table 3).
The Taiwanese version of the EQ-5D ap-
peared to have acceptable concurrent discrimi-
nant validity. The EQ-5D was able to distinguish
between groups of self-reported health statuses.
These patterns suggested that the EQ-5D could
detect differences in HRQOL among people with
different degrees of health (Table 2). In addition,
subjects with serious illness, poor general health,
and more outpatient visits, inpatient visits, and
chronic diseases than others had relatively low
EQ-5D indexes and VAS scores (Table 4). Petrou
and Hockley reported mean EQ-5D and SF-6D
utility scores for each of the self-reported health
subgroups. Both multi-attribute utility measures
significantly differed among subjects who de-
scribed their health status as very good, good,
fair, bad, or very bad (p < 0.001). In addition,
both measures generated utility scores that de-
creased monotonically with deteriorating self-
reported health status (p < 0.001, test for linear
trend).28 Our findings confirmed that HRQOL
was correlated with disease activity. These EQ-5D
results corresponded well with this theory.
Convergent and divergent validities of EQ-5D
dimensions were supported by the expected rela-
tionship with scores on the SF-12 subscales. The
strongest correlations between the measures were
observed between similar constructs, that is, be-
tween the SF-12 MCS with anxiety/depression
on the EQ-5D and between the SF-12 PCS with
pain/discomfort on the EQ-5D. In contrast, weak
correlations were observed between different con-
structs, that is, between the SF-12 MCS and mobil-
ity, self-care, usual activities and pain/discomfort
on the EQ-5D, and between SF-12 PCS and anxi-
ety/depression on the EQ-5D.
Haywood et al determined the test–retest 
reliability of the EQ-5D by studying HRQOL in
patients with ankylosing spondylitis. At 2 weeks,
the ICC was 0.83 for the EQ-5D and 0.80 for 
the VAS (n = 176).29 Konig et al reported that the
agreement between responses and EQ-5D items
ranged from 80.4% (anxiety/discomfort) to 100%
(self-care). For the VAS score and the EQ-5D index,
ICCs were 0.77 and 0.89, respectively (n = 52, in-
terval of 19.5 days).30 Their study demonstrated
consistent results on five dimensions of the EQ-5D
self-classifier, on the VAS, and on the EQ-5D index.
Because this study distribution was strongly skewed
toward improved health states, 96%, 98%, 93%,
67% and 71% of the subjects scored at the top
for the dimensions of mobility, self-care, usual 
activity, pain/discomfort and anxiety/depression,
respectively. This skewing toward improved health
states reflected a homogeneous population, mak-
ing for low reliability.31
Validity and reliability were not as good as they
were in the reference study. One reason might have
been because the study was a postal survey and
not an interview survey. The study design did not
permit us to explain items and answer respon-
dents’ questions face to face. Another reason was
that the retest interval was 3–5 weeks longer than
that of the other study, which was 2 weeks.
This study had a few limitations. First, the re-
sponse rate was low because the study was a postal
survey and because the questionnaire contained
16 items for health status valuation that were dif-
ficult to answer. This low rate raises issues about
the representativeness and generalizability of 
the sample to the whole population of Taiwan.
Second, we used EQ-5D weights derived from the
general population of the United Kingdom and
Japan and SF-12 weights derived from the gen-
eral population of the United States because such
weights are lacking for Taiwan.3,20,21 Third, we used
the Chinese version of the SF-12 to examine the
validity of the EQ-5D. Although the Chinese ver-
sion of the SF-36 has been well validated,16,17 the
SF-12, to our knowledge, has not been validated.
The cross-culturally adapted Taiwanese version
of the EQ-5D was well accepted and demonstrated
acceptable psychometric properties, including
moderate-to-substantial validity and reliability in
a highly educated general Taiwanese population
aged 20–64 years. Our data provide a basis for fur-
ther studies of the Taiwanese EQ-5D instrument.
For example, we will establish the EQ-5D health-
status weights in Taiwan. A potential advantage 
of the EQ-5D is its brevity. When one requires a
T.J. Chang, et al
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limited health instrument with a minimal burden
on respondents for use in routine practice or 
in health economic analyses, we recommend the
EQ-5D self-classifier and the EQ VAS.
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